Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer
Endocrine Oncology · 01.01.2026 · 6 (1)
DOI: 10.1530/eo-25-0114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 17.06.2026. Verfasst von Mathew Gorman und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of Alberta, Edmonton, Alberta, Canada. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Androgen deprivation therapy (ADT) is regularly used to treat locally advanced and metastatic prostate cancer (PCa) with toxicities, including metabolic syndrome (MS) and associated adverse hormonal changes. This study evaluated whether metformin mitigates changes in laboratory biomarkers associated with MS and type II diabetes mellitus (T2DM) in PCa patients receiving ADT. PRIME is a phase III double-blind, randomized controlled trial in which 166 normoglycemic patients with PCa receiving ADT were randomized to receive metformin or placebo. For this study, 47 patients from the metformin arm and 32 patients from the placebo arm underwent serum collection and analysis of the following analytes at baseline, 9, and 12 months: IGF-1, IGFBP1, IGFBP2, IGFBP3, IGFBP7, leptin, adiponectin, GDF15, insulin, C-peptide, GIP, GLP-1, and IL-6. Independent t-tests were used to determine whether significant changes in analytes were evident in patients receiving metformin vs placebo and to evaluate analyte changes from baseline for the metformin and placebo groups separately. Mean leptin values increased markedly in the placebo group and significantly less in the metformin group across all time points. Significant improvements were also observed in IGFBP1, IL-6, C-peptide, and GLP-1 with metformin compared with placebo. GDF15 and IGFBP3 significantly increased compared with baseline with ADT alone. This study demonstrates that metformin can mitigate biomarker changes induced by ADT associated with an increased risk of T2DM and MS. In addition, the attenuated increase in leptin signals a potential for improved PCa outcomes, as high leptin values have been correlated with aggressive disease and worse prognosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Alberta, Edmonton, Alberta, Canada.
- Departments of Medicine and Oncology, McGill University, Montreal, Quebec, Canada.
- Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan, USA.
- Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada.
- Department of Radiation Oncology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
- Dr H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada.
ORCID-Profile: Mathew Gorman
Zitieren
APA
Gorman, M., Usmani, N., Pollak, M. N., Ghosh, S., Elangovan, A., Kim, J., Thoms, J., Bouchard, M., Peacock, M., Wang, Y., Fleshner, N. E., Campbell, H., Vigneault, E., Vincent, F., So, A., Cury, F. L., Quon, H. C., Carlson, R. G., Lambert, C., …, & Eigl, B. J. (2026). Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer. Endocrine Oncology, 6(1). https://doi.org/10.1530/eo-25-0114
Vancouver
Gorman M, Usmani N, Pollak MN, Ghosh S, Elangovan A, Kim J, et al. Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer. Endocrine Oncology. 2026;6(1). doi:10.1530/eo-25-0114
BibTeX
@article{Gorman2026,
author = {Gorman, Mathew and Usmani, Nawaid and Pollak, Michael N and Ghosh, Sunita and Elangovan, Arun and Kim, Julian and Thoms, John and Bouchard, Myriam and Peacock, Michael and Wang, Ye and Fleshner, Neil E and Campbell, Holly and Vigneault, Eric and Vincent, Francois and So, Alan and Cury, Fabio L and Quon, Harvey C and Carlson, Ryan G and Lambert, Carole and Klotz, Laurence and Chi, Kim and Brundage, Michael and Courneya, Kerry S and Eigl, Bernhard J},
title = {Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer},
journal = {Endocrine Oncology},
year = {2026},
volume = {6},
number = {1},
doi = {10.1530/eo-25-0114}
}
EUVIMED